A Randomized Double-Blind Placebo Controlled Trial of Oral Acyclovir in Renal Allograft Recipients
Fifty renal transplant patients were randomized to receive either 800 mg acyclovir by mouth four times daily or identical placebo tablets for prophylaxis of herpes simplex infection. Patients were followed weekly to assess reactivation of herpes simplex, varicella zoster virus, Epstein-Barr virus or...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1993-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/1993/845236 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850223590416318464 |
|---|---|
| author | Walter F Schlech Nancy Meagher Allan D Cohen Philip Belitsky AS MacDonald John C LeBlanc |
| author_facet | Walter F Schlech Nancy Meagher Allan D Cohen Philip Belitsky AS MacDonald John C LeBlanc |
| author_sort | Walter F Schlech |
| collection | DOAJ |
| description | Fifty renal transplant patients were randomized to receive either 800 mg acyclovir by mouth four times daily or identical placebo tablets for prophylaxis of herpes simplex infection. Patients were followed weekly to assess reactivation of herpes simplex, varicella zoster virus, Epstein-Barr virus or cytomegalovirus (CMV) infections. The patients received standard immunosuppressive regimens including cyclosporine A. Acyclovir suppressed secretion of herpes simplex virus in treated patients (P=0.001). Three episodes of mucocutaneous herpes simplex virus occurred in placebo recipients and one in a noncompliant acyclovir recipient. A clinically important difference in graft survival was demonstrated, but because of sample size failed to reach statistical significance (P=0.11). No reactivation of varicella zoster virus, Epstein-Barr virus or CMV infection was detected in either group. Toxicity was limited to central nervous irritability. The authors conclude that high dose oral acyclovir provides effective prophylaxis for prevention of herpes simplex virus infections in renal transplantation and may be associated with increased graft survival, perhaps from suppression of CMV infection. |
| format | Article |
| id | doaj-art-48ee562fb2af4d35989e1c189d6bce44 |
| institution | OA Journals |
| issn | 1180-2332 |
| language | English |
| publishDate | 1993-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases |
| spelling | doaj-art-48ee562fb2af4d35989e1c189d6bce442025-08-20T02:05:52ZengWileyCanadian Journal of Infectious Diseases1180-23321993-01-0142848810.1155/1993/845236A Randomized Double-Blind Placebo Controlled Trial of Oral Acyclovir in Renal Allograft RecipientsWalter F Schlech0Nancy Meagher1Allan D Cohen2Philip Belitsky3AS MacDonald4John C LeBlanc5Victoria General Hospital, Halifax, Nova Scotia, CanadaVictoria General Hospital, Halifax, Nova Scotia, CanadaVictoria General Hospital, Halifax, Nova Scotia, CanadaVictoria General Hospital, Halifax, Nova Scotia, CanadaVictoria General Hospital, Halifax, Nova Scotia, CanadaVictoria General Hospital, Halifax, Nova Scotia, CanadaFifty renal transplant patients were randomized to receive either 800 mg acyclovir by mouth four times daily or identical placebo tablets for prophylaxis of herpes simplex infection. Patients were followed weekly to assess reactivation of herpes simplex, varicella zoster virus, Epstein-Barr virus or cytomegalovirus (CMV) infections. The patients received standard immunosuppressive regimens including cyclosporine A. Acyclovir suppressed secretion of herpes simplex virus in treated patients (P=0.001). Three episodes of mucocutaneous herpes simplex virus occurred in placebo recipients and one in a noncompliant acyclovir recipient. A clinically important difference in graft survival was demonstrated, but because of sample size failed to reach statistical significance (P=0.11). No reactivation of varicella zoster virus, Epstein-Barr virus or CMV infection was detected in either group. Toxicity was limited to central nervous irritability. The authors conclude that high dose oral acyclovir provides effective prophylaxis for prevention of herpes simplex virus infections in renal transplantation and may be associated with increased graft survival, perhaps from suppression of CMV infection.http://dx.doi.org/10.1155/1993/845236 |
| spellingShingle | Walter F Schlech Nancy Meagher Allan D Cohen Philip Belitsky AS MacDonald John C LeBlanc A Randomized Double-Blind Placebo Controlled Trial of Oral Acyclovir in Renal Allograft Recipients Canadian Journal of Infectious Diseases |
| title | A Randomized Double-Blind Placebo Controlled Trial of Oral Acyclovir in Renal Allograft Recipients |
| title_full | A Randomized Double-Blind Placebo Controlled Trial of Oral Acyclovir in Renal Allograft Recipients |
| title_fullStr | A Randomized Double-Blind Placebo Controlled Trial of Oral Acyclovir in Renal Allograft Recipients |
| title_full_unstemmed | A Randomized Double-Blind Placebo Controlled Trial of Oral Acyclovir in Renal Allograft Recipients |
| title_short | A Randomized Double-Blind Placebo Controlled Trial of Oral Acyclovir in Renal Allograft Recipients |
| title_sort | randomized double blind placebo controlled trial of oral acyclovir in renal allograft recipients |
| url | http://dx.doi.org/10.1155/1993/845236 |
| work_keys_str_mv | AT walterfschlech arandomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients AT nancymeagher arandomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients AT allandcohen arandomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients AT philipbelitsky arandomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients AT asmacdonald arandomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients AT johncleblanc arandomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients AT walterfschlech randomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients AT nancymeagher randomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients AT allandcohen randomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients AT philipbelitsky randomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients AT asmacdonald randomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients AT johncleblanc randomizeddoubleblindplacebocontrolledtrialoforalacyclovirinrenalallograftrecipients |